NCT06339190 Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis
| NCT ID | NCT06339190 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Monash University |
| Condition | Neurodegenerative Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2021-08-01 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2021-08-01 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network. The investigators will measure levels of a brain protein, Neurofilament light chain (Nfl), and assess changes in language using speech tests. Participants will have a single blood test and speech test, and will be followed up at 12-months to complete questionnaires and cognitive scales over the phone. The speech test will also be completed again at 12-months. Individuals at risk of a Fronto-temporal dementia syndrome will be eligible to complete optional genetic testing involving an 'at home' saliva sample.
Eligibility Criteria
Inclusion Criteria: * All patients presenting to Eastern Health services with a cognitive complaint or potential neurodegenerative disorder Exclusion Criteria: * Prognosis \<12 months * No cognitive complaint * Patients not involved within the single healthcare network
Contact & Investigator
Prof. Amy Brodtmann, MBBS, FRACP, PhD, FANZAN
PRINCIPAL INVESTIGATOR
Monash University
Frequently Asked Questions
Who can join the NCT06339190 clinical trial?
This trial is open to participants of all sexes, studying Neurodegenerative Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06339190 currently recruiting?
Yes, NCT06339190 is actively recruiting participants. Contact the research team at amy.brodtmann@monash.edu for enrollment information.
Where is the NCT06339190 trial being conducted?
This trial is being conducted at Box Hill, Australia, Wantirna, Australia.
Who is sponsoring the NCT06339190 clinical trial?
NCT06339190 is sponsored by Monash University. The principal investigator is Prof. Amy Brodtmann, MBBS, FRACP, PhD, FANZAN at Monash University. The trial plans to enroll 1,000 participants.